Zai Lab Ltd (ZLAB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $25.74 (-0.27%), Market cap $2.10B, 52-week low–high $16.30 ~ $43.03.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital
Financial statements, price targets, institutional (13F) holdings and related news for Zai Lab Ltd are updated in real time on BlackAll Trade.
Zai Lab Ltd trades at $25.74 (-0.27%). Real-time quotes and charts are available on BlackAll Trade.
Zai Lab Ltd has a market cap of about $2.10B.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and i